SGLT-2 inhibitors and MRAs combo reduces cardiovascular events in patients with CKD

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2022-11-23 14:30 GMT | Update On 2022-11-23 14:30 GMT

A new study published in Diabetes Research and Clinical Practice suggests that combination of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and mineralocorticoid receptor antagonists (MRAs) may reduce cardiovascular (CV) events more than either SGLT-2 inhibitors or MRAs alone.

Renin-angiotensin-aldosterone system (RAAS) inhibitors and mineralocorticoid receptor antagonists are the pillars of disease-modifying therapy in patients with CKD or systolic heart failure to reduce renal disease progression and heart failure hospitalizations. Independent of diabetes status, sodium-glucose cotransporter 2 (SGLT2) inhibitors prolong life in patients with CKD or systolic heart failure and lower the risk of cardiovascular events and renal disease progression. Mineralocorticoid receptor antagonists and sodium-glucose cotransporter-2 inhibitors have both been found to minimize cardiovascular events in people with type 2 diabetes (T2D) and chronic kidney disease (CKD). However, there is little data to support the advantages of their combined usage. As a result, this study was conducted by Shunichiro Tsukamoto and team with the purpose to see how combination treatment with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists affected cardiovascular and renal outcomes in type 2 diabetes patients.

Researchers conducted systematic searches in the MEDLINE, PubMed, EMBASE, and Cochrane Library databases until July 2022. In individuals with T2D and CKD, randomized controlled studies comparing SGLT-2 inhibitors, MRAs, or SGLT-2 inhibitor + MRA combination treatment with placebo were chosen. To compare the therapies indirectly, a network meta-analysis was used. A composite of CV events was the primary outcome.

The key findings of this study were:

1. Eight trials with a total of 36,186 patients were chosen.

2. When compared to the other groups, the combination treatment group had a considerably better main result.

3. Furthermore, the combination treatment was linked to a significant reduction in the risk of hyperkalemia.

In conclusion, from the results of this study it is clearly seen that this combination might be a promising therapy option for people with T2D and CKD.

Reference:

Tsukamoto, S., Morita, R., Yamada, T., Urate, S., Azushima, K., Uneda, K., Kobayashi, R., Kanaoka, T., Wakui, H., & Tamura, K. (2022). Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis. In Diabetes Research and Clinical Practice (p. 110161). Elsevier BV. https://doi.org/10.1016/j.diabres.2022.110161

Article Source : Diabetes Research and Clinical Practice

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Jacinthlyn Sylvia

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

SGLT-2 inhibitors and MRAs combo reduces cardiovascular events in patients with CKD

Similar News

Lipid Accumulation Product strongest Predictor of Diabetes Among Visceral Obesity Indices: Study

Tirzepatide Tied to Lower Risk of Erectile Dysfunction in Men with Type 2 Diabetes: Study Reveals

Osteosarcopenia in Prediabetic Adults Linked to Nearly 3-Fold Higher Osteoarthritis Risk: NHANES Study

Medical Bulletin 05/Jul/2025

Investigational GLP-1 Receptor Agonist effective in Lowering HbA1c in Early Type 2 Diabetes: NEJM

Could Your Saliva Predict Diabetes Risk? Study Finds Out

Early Infections and Obesity in Boys May Reduce Key Male Hormone: Study Suggests

Can Lifestyle Changes Really Prevent Diabetes? Study Provides Insights